Severe hypertriglyceridaemia associated with the use of capecitabine

Netherlands Journal of Medicine

Volumn 70, Issue 2, 2012, Pages 104-

  Polinder Bos, H A ^a   Kok, E E ^a   van de Wiel, A ^a   Spiering, W ^b   Wielders, J P M ^a   Bloemendal, H J ^a  

^a MEANDER MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CAPECITABINE; GEMFIBROZIL; HEMOGLOBIN A1C; OXALIPLATIN;

ADULT; CANCER CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSLIPIDEMIA; GENETIC DISORDER; HUMAN; HYPERTRIGLYCERIDEMIA; LAPAROSCOPIC SURGERY; LETTER; LIPID METABOLISM; LOW FAT DIET; MALE; RECTUM CARCINOMA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; RECTAL NEOPLASMS;

EID: 84858600572     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Stathopoulos GP, Koutantos J, Lazaki H, et al. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer. Anticancer Res. 2007; 27:1653-1666.
2. Bar-Sela G, Haim N. Uncontrolled hypertriglyceridemia induced by Capecitabine. Cancer Chemother Pharmacol. 2009; 63:779-782.
3. Koutras AK, Habeos IG, Vagenakis AG, et al. Capecitabine-induced hypertriglyceridemia. Anticancer Res. 2006;26:2249-514.
4. Kurt M, Babaoglu MO, Yasar U et al. Capecitabine-induced severe hypertriglyceridemia. Ann Pharmacother. 2006;40:328-331.
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.